Nov 4, 4:16 PM ET
Bio-Rad reported third-quarter 2026 net sales of $656.4 million, up 0.5% from a year earlier, and GAAP net income of $458.6 million, compared with a loss of $341.9 million in the prior-year quarter. The GAAP net income reflects a $588.2 million gain from the change in fair market value of its equity securities, while GAAP operating results were a loss of $49.7 million, including restructuring and impairment charges. The company kept its full-year 2026 outlook unchanged.
- Net sales were $656.4 million, up 0.5%; currency-neutral sales rose 0.7%, led by Clinical Diagnostics.
- GAAP net income was $458.6 million, or $17.02 per diluted share, versus a loss of $341.9 million, or $12.70 per share, a year earlier.
- GAAP operating loss was $49.7 million, including $77.2 million of restructuring charges and a $49.8 million impairment of purchased intangibles.
- Non-GAAP diluted income per share was $2.65, up from $2.26; full-year outlook was reaffirmed.
Read the filing on SEC.gov ↗
Aug 4, 4:16 PM ET
On July 31, 2026, Bio-Rad started a restructuring plan that removes certain positions, consolidates functions and closes various facilities, with pre-tax charges estimated at $80 million to $90 million. The same day, it reported second-quarter 2026 net sales of $651.0 million, essentially flat year over year, and reaffirmed its full-year 2026 outlook. GAAP net income rose to $371.4 million mainly because of a gain on its Sartorius AG investment, while non-GAAP net income was $70.2 million, slightly below the prior year.
- Restructuring plan initiated July 31, 2026; estimated pre-tax charges of $80 million to $90 million, mostly termination benefits; expected to be substantially complete by the end of fiscal 2027.
- Q2 2026 net sales $651.0 million vs. $651.6 million in Q2 2025; currency-neutral sales down 1.9 percent.
- GAAP diluted EPS $13.85 vs. $11.67, driven by a change in the fair market value of the Sartorius AG investment; non-GAAP diluted EPS $2.62 vs. $2.61.
- Full-year 2026 outlook reaffirmed: non-GAAP currency-neutral revenue decline of about 3.0 percent to growth of about 0.5 percent; non-GAAP operating margin of about 10.0 to 12.0 percent.
Read the filing on SEC.gov ↗
Apr 30, 4:17 PM ET
Bio-Rad reported first-quarter 2026 net sales of $592.1 million, up 1.1% from a year earlier, but a $738.2 million loss from the change in fair market value of its equity securities and loan receivable led to a GAAP net loss of $527.1 million, or $19.55 per diluted share. The company also lowered its full-year 2026 non-GAAP outlook, which matters to shareholders because the currency-neutral revenue range and operating margin range both moved down.
- Q1 2026 net sales were $592.1 million, up 1.1%; currency-neutral sales fell 4.2%.
- GAAP net loss was $527.1 million, or $19.55 per diluted share, versus net income of $64.0 million, or $2.29, in Q1 2025.
- Non-GAAP diluted earnings per share were $1.89, versus $2.54 a year earlier; free cash flow was $78.1 million.
- 2026 outlook: currency-neutral revenue now a decline of about 3.0% to growth of about 0.5%, versus prior growth of 0.5% to 1.5%; non-GAAP operating margin now about 10.0% to 12.0%, versus prior 12.0% to 12.5%.
Read the filing on SEC.gov ↗
Apr 24, 4:30 PM ET
At its April 21, 2026 annual meeting, Bio-Rad stockholders approved an amended 2017 Incentive Award Plan that adds 335,000 shares and extends the plan's expiration to March 18, 2036. Stockholders also elected the six nominated directors, ratified KPMG LLP as auditor for fiscal 2026, and approved executive compensation on an advisory basis. A stockholder proposal on the dual class capital structure was not approved.
- Amended 2017 Incentive Award Plan approved, adding 335,000 shares and extending expiration to March 18, 2036
- Dual class capital structure proposal received 1,469,297 votes for and 5,459,554 votes against, and was not approved
- KPMG LLP ratified as independent auditor for the fiscal year ending December 31, 2026, with 7,037,199 votes for and 38,994 against
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.